GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity

Autor: Sarah Falk, Jonas Petersen, Charlotte Svendsen, Cesar R. Romero-Leguizamón, Søren Heide Jørgensen, Nathalie Krauth, Mette Q. Ludwig, Kathrine Lundø, Urmas Roostalu, Grethe Skovbjerg, Duy Anh Gurskov Nielsen, Aske Lykke Ejdrup, Tune H. Pers, Oksana Dmytriyeva, Jacob Hecksher-Sørensen, Ulrik Gether, Kristi A. Kohlmeier, Christoffer Clemmensen

Publikováno v: Falk, S, Petersen, J O, Svendsen, C S A, Leguizamon, C R R, Jørgensen, S H, Krauth, N, Ludwig, M Q, Lundø, K, Roostalu, U, Hjort-Gregersen, G S, Nielsen, D A G, Ejdrup, A L, Pers, T H, Dmytriyeva, O, Hecksher-Soerensen, J, Gether, U, Kohlmeier, K A & Clemmensen, C 2023, ' GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity ', Cell Reports, vol. 42, no. 5, 112466 . https://doi.org/10.1016/j.celrep.2023.112466

Glucagon-like peptide-1 receptor (GLP-1R) agonists promote nicotine avoidance. Here, we show that the crosstalk between GLP-1 and nicotine extends beyond effects on nicotine self-administration and can be exploited pharmacologically to amplify the an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e039f98ee08a450e7a8844a6cc07ce38
https://curis.ku.dk/ws/files/346487639/1_s2.0_S2211124723004771_main.pdf